94 related articles for article (PubMed ID: 25966772)
21. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
[TBL] [Abstract][Full Text] [Related]
22. Histopathology of C Cells and Medullary Thyroid Carcinoma.
Schmid KW
Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
[TBL] [Abstract][Full Text] [Related]
23. Early malignant progression of hereditary medullary thyroid cancer.
Machens A; Niccoli-Sire P; Hoegel J; Frank-Raue K; van Vroonhoven TJ; Roeher HD; Wahl RA; Lamesch P; Raue F; Conte-Devolx B; Dralle H;
N Engl J Med; 2003 Oct; 349(16):1517-25. PubMed ID: 14561794
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemistry of medullary thyroid carcinoma and C-cell hyperplasia by an affinity-purified anti-human calcitonin antiserum.
Hayashida CY; Alves VA; Kanamura CT; Ezabella MC; Abelin NM; Nicolau W; Bisi H; Toledo SP
Cancer; 1993 Aug; 72(4):1356-63. PubMed ID: 8339225
[TBL] [Abstract][Full Text] [Related]
25. Isthmus-preserving total bilobectomy: an adequate operation for C-cell hyperplasia.
Wahl RA; Vorländer C; Kriener S; Pedall J; Spitza M; Hansmann ML
World J Surg; 2006 May; 30(5):860-71. PubMed ID: 16680601
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and management of medullary thyroid carcinoma.
Massoll N; Mazzaferri EL
Clin Lab Med; 2004 Mar; 24(1):49-83. PubMed ID: 15157557
[TBL] [Abstract][Full Text] [Related]
27. [Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II].
Engelbach M; Kunt T; Kann P; Manfras B; Hankeln T; Forst T; Pfützner A; Heerdt S; Walgenbach S; Lehnert H; Beyer J
Dtsch Med Wochenschr; 2000 Jan; 125(3):37-44. PubMed ID: 10681997
[TBL] [Abstract][Full Text] [Related]
28. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
[TBL] [Abstract][Full Text] [Related]
29. Proliferative activity in C-cell hyperplasia and medullary thyroid carcinoma. Evaluation by PCNA immunohistochemistry and AgNORs staining.
Matias-Guiu X; Peiro G; Esquius J; Oliva E; Cabezas R; Colomer A; Prat J
Pathol Res Pract; 1995 Feb; 191(1):42-7. PubMed ID: 7651932
[TBL] [Abstract][Full Text] [Related]
30. C-cell hyperplasia.
Guyétant S; Bléchet C; Saint-André JP
Ann Endocrinol (Paris); 2006 Jun; 67(3):190-7. PubMed ID: 16840909
[TBL] [Abstract][Full Text] [Related]
31. [Clinical follow up and histological findings of patients with MEN2 treated with prophylactic thyroidectomy].
Roldán Pérez S; Cabello Laureano R; Fernández-Pineda I; Aspiazu Salinas D; Martínez Criado Y; De Agustín Asensio JC
Cir Pediatr; 2012 Jul; 25(3):159-62. PubMed ID: 23480014
[TBL] [Abstract][Full Text] [Related]
32. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature].
de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT
Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023
[TBL] [Abstract][Full Text] [Related]
33. Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation.
Vantyghem MC; Pigny P; Leteurtre E; Leclerc L; Bauters C; Douillard C; D'Herbomez M; Carnaille B; Proye C; Wemeau JL; Lecomte-Houcke M
Thyroid; 2004 Oct; 14(10):842-7. PubMed ID: 15588381
[TBL] [Abstract][Full Text] [Related]
34. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
Moore SW; Appfelstaedt J; Zaahl MG
J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
[TBL] [Abstract][Full Text] [Related]
35. Current management of medullary thyroid cancer.
Sippel RS; Kunnimalaiyaan M; Chen H
Oncologist; 2008 May; 13(5):539-47. PubMed ID: 18515739
[TBL] [Abstract][Full Text] [Related]
36. Medullary thyroid carcinoma: surgical treatment advances.
Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
[TBL] [Abstract][Full Text] [Related]
37. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma].
Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799
[TBL] [Abstract][Full Text] [Related]
38. Medullary thyroid carcinoma.
Pacini F; Castagna MG; Cipri C; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
[TBL] [Abstract][Full Text] [Related]
39. Thyroid C-cell hyperplasia in an adolescent with neurofibromatosis type 1.
Segni M; Massa R; Bonifacio V; Tartaglia F; Pucarelli I; Marzullo A; Pasquino AM
Horm Res; 2001; 56(1-2):63-6. PubMed ID: 11815730
[TBL] [Abstract][Full Text] [Related]
40. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
